SGMO

Sangamo Therapeutics Inc. (SGMO) | Rumor.io

Sangamo Therapeutics

SGMO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)68%

Price to earnings ratio-0.17

Market capitalization30.7M

Earnings per share-0.38

Dividend yield (TTM)—

Revenue (annual)39.6M

Net income (annual)-122.9M

Social

What share of all stock conversation is about SGMO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% -0.01	0% +0	0.01% -0.02

Jul 9

The equity committee of Sangamo Therapeutics, Inc. (SGMO) has been formed, aiming to recover value for shareholders through a Chapter 11 process, with potential bids for the company's assets ranging from $300-400 million.
Dirk, a significant SGMO shareholder, has invested $1.6 million in the company, expecting a potential return of around $6.4 million if the company's assets are sold for $330 million, with $170 million allocated for debt and liabilities.
The formation of an ad hoc group of equity holders, represented by law firms Orrick, Herrington & Sutcliffe LLP and Morris James LLP, aims to monitor and participate in the bankruptcy proceedings on behalf of shareholders, with a focus on maximizing potential payouts.

Generated by AI

Sentiment

Of the messages about SGMO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	49.28% +49.28	44.72% +25.46	57.6% -17.24	69.24% -8.43
Bearish	50.72% -49.28	55.28% -25.46	42.4% +17.24	30.76% +8.43

Bullish· Jun 23

Sangamo Therapeutics, Inc. (SGMO) may receive valuable assets or bids during its Chapter 11 process, potentially benefiting shareholders.
The company's sale of assets to Lilly and Astellas could lead to a revaluation of the assets, making it harder to argue that the bids represent fair value if SGMO trades above $0.50.
SGMO's sale process may attract new bidders, with Astellas being a natural fit for the Fabry assets, potentially leading to a sale price of over $200 million.

Bearish· Jun 24

The company's management, led by CEO Sandy, has been criticized for making poor decisions, including diluting shares and rejecting multiple offers, which led to the company's bankruptcy.
The company's science was not the primary reason for its failure, but rather commercialization missteps, such as failing to secure venture capital funding and lacking a clear market strategy.
The company's bankruptcy was a result of a combination of factors, including poor management, lack of a clear market strategy, and the decision to go bankrupt, which drove the stock price to nearly zero and resulted in a fire sale of the company's assets.

Generated by AI

Topics

Of the messages about SGMO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	10.25%
Announcements	79.35%	85.29%	93.12%	75.32%
Controversies	19.57%	14.22%	6.26%	2.49%
Earnings	0%	0%	0%	1.46%
Macro	0%	0%	0%	5.75%
Technical Analysis	1.09%	0.49%	0.62%	4.73%

Earnings· Aug 8

Sangamo Therapeutics ($SGMO) reports Q2 earnings of -$0.17 EPS and $21.42M revenue, missing estimates by $0.02.
The company's revenue for the quarter ended June 30, 2018 was $21.4M, up from $8.3M in the same period last year.
Sangamo Therapeutics' earnings results missed the Estimize EPS consensus by 3c and the Estimize revenue consensus by $7.53M.

Analysts· Nov 14

JPMorgan downgraded Sangamo Therapeutics (SGMO) from Overweight to Neutral with a price target of $11 due to skepticism around the efficacy of genetic therapies.
The downgrade occurred despite JPMorgan increasing its position in SGMO, which some view as contradictory and potentially misleading to investors.
Wells Fargo maintains an OUTPERFORM rating on SGMO with a price target of $39, citing the company's progress in 3Q18 and the value of its science, which it believes is being underestimated by the market.

Announcements· Jun 23

Sangamo Therapeutics, Inc. (SGMO) has filed for Chapter 11 bankruptcy and entered into asset sale agreements with Eli Lilly and Astellas, with Eli Lilly acquiring key platforms and the ST-506 program for $50M and Astellas acquiring the Fabry program for up to $50M.
The asset sale is expected to generate a total of $514.3MM, with shareholders potentially receiving approximately $1/share, while debt and fees would be covered by the sale.
The company's gene therapies, ST-503 and ST-920, are expected to be valued highly, with investments often ranging from $300 million to over $1 billion for successful gene therapies, compared to $1-2.5 billion for conventional drugs.

Technical Analysis· Aug 6

$SGMO is creating higher lows, indicating a potential bullish trend.
A double bottom formation is visible on the weekly chart, with a target price of $2.65.
A bull flag is forming, with key resistance at $1.21-$1.30, and a potential short squeeze incoming if the price breaks above $1.15.

Generated by AI

Community

Of the messages about SGMO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	91.8%	92.48%	92.26%	86.77%
Newcomers	8.2%	7.52%	7.74%	13.23%

Regulars· Jul 2

The company has built up substantial tax loss carry-forwards (NOLs) over many years, which can benefit a profitable pharmaceutical company for tax purposes.
A strategic buyer could acquire Sangamo's technology, pipeline, and intellectual property, as well as the tax loss carry-forwards, in one fell swoop.
The voluntary Chapter 11 filing and auction process may be designed to screw over long-term shareholders, with the company's assets being sold off at a fraction of their value, and expenses kept high up to the end.

Newcomers· Jun 23

Sangamo Therapeutics has filed for Chapter 11 bankruptcy and entered stalking horse asset sale agreements with Eli Lilly and Astellas for up to $100M.
The company's Chapter 11 filing and asset sale agreements with Lilly and Astellas may wipe out common equity value to zero.
Sangamo's assets, including over 140 active patents, will be sold to satisfy senior secured creditors and debtor-in-possession lenders, with a potential sale price of up to $100M.

Generated by AI

Also Discussed

Investors talking about SGMO also mention

#	Name	Attention
1	Editas Medicine, Inc.EDIT	0%+0
2	Intellia Therapeutics, Inc.NTLA	0%+0
3	CRISPR Therapeutics AGCRSP	0%0
4	uniQure N.V.QURE	0.02%+0.01
5	BioMarin Pharmaceutical IncBMRN	0%+0
6	Cellectis S.A. ADRCLLS	0%0
7	Regenxbio Inc.RGNX	0%+0
8	Alnylam Pharmaceuticals, Inc.ALNY	0%0
9	Sarepta Therapeutics, Inc.SRPT	0%-0.01
10	Solid Biosciences Inc.SLDB	0.3%new

Sangamo Therapeutics Inc.

Healthcare
Biotechnology

Sangamo Therapeutics Inc. is a clinical-stage genomic medicine company focused on developing innovative therapies to treat serious diseases. Its primary purpose is to translate advanced genomic technologies into transformative medicines for patients with conditions such as Fabry disease, hemophilia A, and immune-mediated rejection in kidney transplantation. Key clinical-stage product candidates include ST-920, a gene therapy in Phase 1/2 for Fabry disease; TX200, a CAR-Treg therapy in Phase 1/2 for preventing rejection in HLA-A2 mismatched kidney transplants; and SB-525, a gene therapy in Phase 3 for moderately severe to severe hemophilia A. The company also advances preclinical programs targeting tauopathies, ALS/FTD, and Huntington's disease. Sangamo Therapeutics Inc. maintains strategic partnerships with leading biopharma companies like Pfizer, Novartis, and Sanofi to support its pipeline development. Operating in the genomic medicine sector, it plays a significant role in advancing gene therapy and cell therapy solutions for rare genetic disorders and neurological conditions in the United States.

Website

Location

501 Canal Blvd

Richmond, CA, 94804

United States

Social

What share of all stock conversation is about SGMO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% -0.01	0% +0	0.01% -0.02

Jul 9

The equity committee of Sangamo Therapeutics, Inc. (SGMO) has been formed, aiming to recover value for shareholders through a Chapter 11 process, with potential bids for the company's assets ranging from $300-400 million.
Dirk, a significant SGMO shareholder, has invested $1.6 million in the company, expecting a potential return of around $6.4 million if the company's assets are sold for $330 million, with $170 million allocated for debt and liabilities.
The formation of an ad hoc group of equity holders, represented by law firms Orrick, Herrington & Sutcliffe LLP and Morris James LLP, aims to monitor and participate in the bankruptcy proceedings on behalf of shareholders, with a focus on maximizing potential payouts.

Generated by AI

Sentiment

Of the messages about SGMO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	49.28% +49.28	44.72% +25.46	57.6% -17.24	69.24% -8.43
Bearish	50.72% -49.28	55.28% -25.46	42.4% +17.24	30.76% +8.43

Bullish· Jun 23

Sangamo Therapeutics, Inc. (SGMO) may receive valuable assets or bids during its Chapter 11 process, potentially benefiting shareholders.
The company's sale of assets to Lilly and Astellas could lead to a revaluation of the assets, making it harder to argue that the bids represent fair value if SGMO trades above $0.50.
SGMO's sale process may attract new bidders, with Astellas being a natural fit for the Fabry assets, potentially leading to a sale price of over $200 million.

Bearish· Jun 24

The company's management, led by CEO Sandy, has been criticized for making poor decisions, including diluting shares and rejecting multiple offers, which led to the company's bankruptcy.
The company's science was not the primary reason for its failure, but rather commercialization missteps, such as failing to secure venture capital funding and lacking a clear market strategy.
The company's bankruptcy was a result of a combination of factors, including poor management, lack of a clear market strategy, and the decision to go bankrupt, which drove the stock price to nearly zero and resulted in a fire sale of the company's assets.

Generated by AI

Topics

Of the messages about SGMO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	10.25%
Announcements	79.35%	85.29%	93.12%	75.32%
Controversies	19.57%	14.22%	6.26%	2.49%
Earnings	0%	0%	0%	1.46%
Macro	0%	0%	0%	5.75%
Technical Analysis	1.09%	0.49%	0.62%	4.73%

Earnings· Aug 8

Sangamo Therapeutics ($SGMO) reports Q2 earnings of -$0.17 EPS and $21.42M revenue, missing estimates by $0.02.
The company's revenue for the quarter ended June 30, 2018 was $21.4M, up from $8.3M in the same period last year.
Sangamo Therapeutics' earnings results missed the Estimize EPS consensus by 3c and the Estimize revenue consensus by $7.53M.

Analysts· Nov 14

JPMorgan downgraded Sangamo Therapeutics (SGMO) from Overweight to Neutral with a price target of $11 due to skepticism around the efficacy of genetic therapies.
The downgrade occurred despite JPMorgan increasing its position in SGMO, which some view as contradictory and potentially misleading to investors.
Wells Fargo maintains an OUTPERFORM rating on SGMO with a price target of $39, citing the company's progress in 3Q18 and the value of its science, which it believes is being underestimated by the market.

Announcements· Jun 23

Sangamo Therapeutics, Inc. (SGMO) has filed for Chapter 11 bankruptcy and entered into asset sale agreements with Eli Lilly and Astellas, with Eli Lilly acquiring key platforms and the ST-506 program for $50M and Astellas acquiring the Fabry program for up to $50M.
The asset sale is expected to generate a total of $514.3MM, with shareholders potentially receiving approximately $1/share, while debt and fees would be covered by the sale.
The company's gene therapies, ST-503 and ST-920, are expected to be valued highly, with investments often ranging from $300 million to over $1 billion for successful gene therapies, compared to $1-2.5 billion for conventional drugs.

Technical Analysis· Aug 6

$SGMO is creating higher lows, indicating a potential bullish trend.
A double bottom formation is visible on the weekly chart, with a target price of $2.65.
A bull flag is forming, with key resistance at $1.21-$1.30, and a potential short squeeze incoming if the price breaks above $1.15.

Generated by AI

Community

Of the messages about SGMO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	91.8%	92.48%	92.26%	86.77%
Newcomers	8.2%	7.52%	7.74%	13.23%

Regulars· Jul 2

The company has built up substantial tax loss carry-forwards (NOLs) over many years, which can benefit a profitable pharmaceutical company for tax purposes.
A strategic buyer could acquire Sangamo's technology, pipeline, and intellectual property, as well as the tax loss carry-forwards, in one fell swoop.
The voluntary Chapter 11 filing and auction process may be designed to screw over long-term shareholders, with the company's assets being sold off at a fraction of their value, and expenses kept high up to the end.

Newcomers· Jun 23

Sangamo Therapeutics has filed for Chapter 11 bankruptcy and entered stalking horse asset sale agreements with Eli Lilly and Astellas for up to $100M.
The company's Chapter 11 filing and asset sale agreements with Lilly and Astellas may wipe out common equity value to zero.
Sangamo's assets, including over 140 active patents, will be sold to satisfy senior secured creditors and debtor-in-possession lenders, with a potential sale price of up to $100M.

Generated by AI

Sangamo Therapeutics

Social

Jul 9

Sentiment

Bullish· Jun 23

Bearish· Jun 24

Topics

Earnings· Aug 8

Analysts· Nov 14

Announcements· Jun 23

Technical Analysis· Aug 6

Community

Regulars· Jul 2

Newcomers· Jun 23

Also Discussed

Sangamo Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Jul 9

Sentiment

Bullish· Jun 23

Bearish· Jun 24

Topics

Earnings· Aug 8

Analysts· Nov 14

Announcements· Jun 23

Technical Analysis· Aug 6

Community

Regulars· Jul 2

Newcomers· Jun 23